Tesamorelin evidence check
Tesamorelin is proven for general weight loss.
Verdict
Misleading with an evidence grade of F. Tesamorelin evidence and labeling support a narrow HIV-associated lipodystrophy context. General weight-loss claims are misleading because the prescribing information says it is not indicated for weight-loss management.
What this means
This grade applies only to the claim on this page, including the stated population and outcome. A supported claim in one context should not be stretched into a broader peptide promise.
What this does not mean
This page is not dosing guidance, a protocol, a recommendation to buy or use a product, or personal medical advice. High-risk claims need narrow wording, source links, and human review before publication.
Source trail
Evidence is listed by source type so you can see whether the claim rests on labeling, human studies, preclinical work, anecdotes, or vendor language.
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Randomized human trial source for tesamorelin in HIV-associated abdominal fat accumulation.
Open sourceEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Phase 3 pooled human trial source supporting the HIV-associated abdominal-fat context, not broad general weight loss.
Open sourceEGRIFTA SV prescribing information
FDA prescribing information frames tesamorelin use around HIV-associated lipodystrophy and states that it is not indicated for weight-loss management.
Open sourceDisclosure
Disclosure: Some links may be affiliate links. Peptide Fact Checks may earn a commission if you use them. That does not affect evidence grades, verdicts, or vendor transparency notes.